Werewolf Therapeutics Appoints Mike Sherman to its Board of Directors

May 27, 2021

Over 30 years of experience in advancing therapeutics to commercial launch and driving companies to successful operations and strategic transactions.

April 5, 2024

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

WATERTOWN, Mass., April 05, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

April 4, 2024

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

WATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

March 7, 2024

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

Share this article: